Organization Statistics
Avg Compliance Rate
48.60%
Compliant Trials
486
Incompliant submissions
514
Total Organizations
46697
Total trials
1000
Filter Organizations
Compare Organization Compliance Rates
Showing 2350 of 46697 entries
View as:
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 2
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 3
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 8
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 4
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 8
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 291
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
0.0% Compliant
Total: 1
Funding: N/A
Compliant:
0
Late:
0
Wilson LCB:
N/A
Reporting Rate: N/A
Compliance Rate: 0.0%
| Sponsor | Funding Source | Total Trials | Reporting Rate | Compliant Trials | Late Submissions | Compliance Rate | Wilson LCB Score | Email Domain | Created Date |
|---|---|---|---|---|---|---|---|---|---|
| Amplified Sciences Inc | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amplified Sciences Inc.temp.org | 2025-07-14 |
| Amplitude Vascular Systems, Inc. | - | 2 | 0.0% | 0 | 0 | 0.0% | - | Amplitude Vascular Systems, Inc..temp.org | 2025-07-14 |
| Amr Abdelaal | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr Abdelaal.temp.org | 2025-07-14 |
| Amr Anwar Mohamed Ellithy Yousef | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr Anwar Mohamed Ellithy Yousef.temp.org | 2025-07-14 |
| Amr Azab Abd El-Fattah | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr Azab Abd El-Fattah.temp.org | 2025-07-14 |
| Amr El Sayed Khalifa | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr El Sayed Khalifa.temp.org | 2025-07-14 |
| Amr Gamaleldin Mahmoud Khalil Gendya | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr Gamaleldin Mahmoud Khalil Gendya.temp.org | 2025-07-14 |
| Amr Hafez | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr Hafez.temp.org | 2025-07-14 |
| Amr Mohamed MD | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr Mohamed MD.temp.org | 2025-07-14 |
| Amr Mohamed Sedik | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr Mohamed Sedik.temp.org | 2025-07-14 |
| Amr Mohsen Mohamed Abo Khatwa | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr Mohsen Mohamed Abo Khatwa.temp.org | 2025-07-14 |
| Amr kamel khalil Ahmed | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amr kamel khalil Ahmed.temp.org | 2025-07-14 |
| Amref Health Africa | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amref Health Africa.temp.org | 2025-07-14 |
| Amrinder Babbra | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amrinder Babbra.temp.org | 2025-07-14 |
| Amrit Sinha | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amrit Sinha.temp.org | 2025-07-14 |
| Amrita Institute of Medical Sciences & Research Center | - | 3 | 0.0% | 0 | 0 | 0.0% | - | Amrita Institute of Medical Sciences & Research Center.temp.org | 2025-07-14 |
| Amrita Vishwa Vidyapeetham | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amrita Vishwa Vidyapeetham.temp.org | 2025-07-14 |
| Amro M. Hetta, M.Sc. | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amro M. Hetta, M.Sc..temp.org | 2025-07-14 |
| Amryt Pharma | - | 8 | 0.0% | 0 | 0 | 0.0% | - | Amryt Pharma.temp.org | 2025-07-14 |
| Amryt Research Limited | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amryt Research Limited.temp.org | 2025-07-14 |
| Amsterdam Institute for Global Health and Development | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amsterdam Institute for Global Health and Development.temp.org | 2025-07-14 |
| Amsterdam Molecular Therapeutics | - | 4 | 0.0% | 0 | 0 | 0.0% | - | Amsterdam Molecular Therapeutics.temp.org | 2025-07-14 |
| Amsterdam UMC | - | 8 | 0.0% | 0 | 0 | 0.0% | - | Amsterdam UMC.temp.org | 2025-07-14 |
| Amsterdam UMC, location VUmc | - | 291 | 0.0% | 0 | 0 | 0.0% | - | Amsterdam UMC, location VUmc.temp.org | 2025-07-14 |
| Amsterdam University Medical Center | - | 1 | 0.0% | 0 | 0 | 0.0% | - | Amsterdam University Medical Center.temp.org | 2025-07-14 |